Skip to main content
OpenTrials
Completed

NCT Number: NCT00554190

Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel

The purpose of this study is to evaluate the safety and effectiveness of AdvaCoat® sinus gel, a nasal/sinus dressing, for adhesion prevention following endoscopic ethmoid sinus surgery. Subjects were randomized to receive AdvaCoat applied to the right or left middle meatus tissues and Merogel applied to the middle meatus tissues on the opposite side.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Alabama Nasal & Sinus Center, Birmingham, Alabama, United States

Loading trial locations.

About this study

Chronic rhinosinusitis is a very common condition, affecting 35 million Americans each year. All paranasal sinuses need ventilation to prevent infection and inflammation. Sinus ventilation occurs through the ostia into the nose. When rhinosinusitis occurs, the mucous membranes of the sinuses become swollen, resulting in ostia closure. Functional endoscopic sinus surgery (FESS) is a minimally invasive surgical procedure that opens the sinus ostia.

The most common unwanted side effect of the FESS procedure is the formation of adhesions (fibrous bands) in the area of surgery. These bands (adhesions) can prevent proper ventilation and drainage from the paranasal sinuses.

Various hyaluronan based biomaterials are now available and in common use to provide a post-surgical nasal dressing which is absorbable, can prevent adhesion formation, and eliminate the pain and tissue abrasion caused by removal of non-absorbable nasal packing.

AdvaCoat is a bioresorbable hyaluronan gel that conforms to mucosal surfaces and provides a post-surgical nasal dressing to prevent adhesion formation as tissues heal.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients who:

  • Have bilateral chronic rhinosinusitis confirmed by physical exam, clinical history, and prior radiography
  • Have bilateral ethmoid sinus disease
  • Are scheduled for bilateral anterior or total ethmoidectomy

Exclusion criteria

  • Unilateral ethmoid sinus disease
  • Partial resection of middle turbinates, unilateral or bilateral

Treatment and study plan

AdvaCoat sinus gel

Device

A sterile,viscoelastic, bioresorbable gel composed of highly purified hyaluronan, a naturally occurring constituent of tissues in the body

Merogel Injectable

Device

Bioresorbable hyaluronic acid product

Other names: Merogel

Primary outcomes

  1. Number of Participants With Adhesion as Measured by the Synechia (Adhesion) Scale

    Time frame: Post-operative through 60 days

    Synechia (adhesion) scale range of 0 = No visible synechia to 3 = Complete scarring between the middle turbinate and lateral nasal wall was used in the assessment.

  2. Number of Participants With Solicited and Recorded Adverse Events

    Time frame: Post-operative through 60 days

    All reported events were coded to a standard set of terms using the MedDRA adverse event dictionary. Adverse events were listed and summarized.

Sponsors and collaborators

Lead sponsor

Carbylan Therapeutics, Inc.

Industry

Registry information

Official study title

A Prospective, Multi-Center, Randomized, Controlled, Subject-Blinded Study to Evaluate the Safety and Effectiveness of AdvaCoat Sinus Gel Following Endoscopic Ethmoid Sinus Surgery

Important dates

Study start
2007
Primary completion
2007
Study completion
2007
First posted
Nov 6, 2007
Registry last updated
Apr 23, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.